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Abstract
Background Perilipin2 (Plin2) belongs to a family of five highly conserved proteins, known for their role in lipid storage.
Recent data indicate that Plin2 has an important function in cell metabolism and is involved in several human pathologies,
including liver steatosis and Type II diabetes. An association between Plin2 and lower muscle mass and strength has been
found in elderly and inactive people, but its function in skeletal muscle is still unclear. Here, we addressed the role of Plin2
in adult muscle by gain and loss of function experiments.
Methods By mean of in vivo Plin2 down-regulation (shPlin2) and overexpression (overPlin2) in murine tibialis anterior mus-
cle, we analysed the effects of Plin2 genetic manipulations on myofiber size and lipid composition. An analysis of skeletal mus-
cle lipid composition was also performed in vastus lateralis samples from young and old patients undergoing hip surgery.
Results We found that Plin2 down-regulation was sufficient to induce a 30% increase of myofiber cross-sectional area,
independently of mTOR pathway. Alterations of lipid content and modulation of genes involved in lipid synthesis occurred in
hypertrophic muscles. In particular, we showed a decrease of triglycerides, ceramides, and phosphatidylcoline:phosphatidyleth-
anolamine ratio, a condition known to impact negatively on muscle function. Plin2 overexpression did not change fibre size;
however, lipid composition was strongly affected in a way that is similar to that observed in human samples from old patients.
Conclusions Altogether these data indicate that Plin2 is a critical mediator for the control of muscle mass, likely, but maybe
not exclusively, through its critical role in the regulation of intracellular lipid content and composition.
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Introduction
In last years, the accumulation of lipid intermediates in non-
adipose tissues has become the focus of intense study, given
the effects that excess ectopic fat storage has on the develop-
ment of several metabolic disorders.1 In cells, triglycerides and
cholesterol are stored within lipid droplets (LDs), dynamic
structures evolutionary conserved from yeast to mammals
and characterized by a core of neutral lipids, mainly sterol es-
ters and triacylglycerols (TAG), surrounded by a monolayer of
phospholipids (PL). LDs membrane is decorated by key
proteins involved in several metabolic processes, such as fat
storage, regulation of lipid homeostasis (synthesis and degra-
dation), and protection against lipotoxicity. Among these
proteins there are: lipid-synthesis factors, such as sterol
regulatory element-binding protein-1 (SREBP-1) and acyl-
CoA:diacylglycerol acyltransferase 2 (DGAT2); lipases, such as
adipose tissue triacylglycerol lipase (ATGL); and structural pro-
teins, such as Perilipins that are the most abundant. Perilipins
belong to a family of five proteins (Plin1, Plin2/ADRP/
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adipophilin, Plin3/Tip47, Plin4/S3–12, and Plin5/OXPAT) that
attracted great interest for their role in lipid metabolism.2,3
Recent findings showed that the modification of perilipins
expression dysregulates intracellular lipid deposition, accumu-
late diacylglycerols (DAG) or ceramides, impair cellular
function, and cause lipotoxicity.4,5
Plin2 plays a fundamental role in lipid storage and is widely
expressed in active metabolic tissues, including skeletal mus-
cle.6 We recently reported the accumulation of Plin2 in hu-
man skeletal muscles biopsies during ageing and inactivity.7
Interestingly, Plin2 expression in vastus lateralismuscle corre-
lates with lower muscle mass and strength and mirrors the in-
creased expression of atrophy-related genes such as Atrogin-
1 and MuRF-1, as well as p53.7,8 Plin2 protein is stable only
when associated to LDs; otherwise, it is targeted to
proteasomal degradation.9 Therefore, the amount of Plin2
protein reflects the intracellular lipid content. Several studies
showed a correlation between high levels of Plin2 and meta-
bolic disorders, including liver steatosis, insulin resistance,
type 2 diabetes, atherosclerosis, and cardiovascular dis-
eases.6 Conversely, in mice, Plin2 deficiency attenuates he-
patic steatosis and improves fatty liver metabolism. In
particular, liver of Plin2-KO mice displays a significant de-
crease of two important key regulators of lipid synthesis:
SREBP1 and DGAT2,10 suggesting a role for Plin2 in the con-
trol of lipid homeostasis-related genes. Indeed, Plin2 deletion
dramatically reduces TAG and cholesterol levels as well as
desaturation and elongation of hepatic neutral lipid species
in liver.11 Moreover, a recent work in Drosophila showed that
dHDAC6-dependent Plin2 degradation reduces age-
dependent ectopic fat accumulation and protects the organ-
ism from tissue dysfunction during ageing.12 Altogether,
these evidences suggest that Plin2 plays an important role
in modulating lipid metabolism.
Skeletal muscle is another important player in lipid metab-
olism. In fact, intracellular accumulation of fatty acids has
been reported to affect both muscle mass and function.13
The role of Plin2 in muscle physiopathology has not been
yet dissected. Based on the evidence that Plin2 accumulates
in muscles of unhealthy aged people, we exploited murine
models in order to unravel the role of Plin2 in adult skeletal
muscle. Here, we show the effects of Plin2 down-regulation
or overexpression on cross-sectional area (CSA) and lipid
content in adult skeletal muscles of mice. Our data show
that Plin2 down-regulation in adult tibialis anterior muscle
is sufficient to increase myofibers size of 30%, while its over-
expression does not elicit any effect in an acute time win-
dow. Simultaneously, lipid content and in particular TAG
and ceramides were altered in hypertrophic myofibers. Fi-
nally, the down-regulation of Plin2 expression in denervated
muscles almost completely prevented muscle loss. These
findings support the hypothesis that Plin2 controls muscle
mass, likely through a modulation of the intramuscular
lipidome.
Materials and methods
Mice
Three-months-old C57BL/6J male mice were purchased from
Charles River Laboratories. Mice were housed in an environ-
mentally controlled room (23°C, 12 h light/12 h dark cycle)
and provided food (Mucedola srl standard diet) and water
ad libitum. After a period of acclimatization, mice were sub-
jected to surgical procedures (electroporation and denerva-
tion) as described in Milan et al.14 Mouse procedures were
all approved by the Italian Ministry of Health, protocol num-
ber 1060/2015PR.
Human samples
In the present study, patients of different age, 9 young (5
males and 4 females, mean age: 31.5 ± 6.0; mean BMI:
25.9 ± 4.4) and 10 old (5 males and 5 females, mean age:
84.9 ± 4.7; mean BMI: 26.8 ± 3.3), who underwent surgery
for hip dysplasia, were included. Written informed consent
was obtained from all patients, and the study was approved
by the responsible Ethical Committee of Istituto Ortopedico
Rizzoli (protocol no. 10823, issued on 26 April 2010) (Bolo-
gna–Italy). During surgery, biopsies from vastus lateralis (VL)
muscle were obtained and immediately snap frozen in liquid
nitrogen and stored at 80°C. Age (>20 years) and ability to
provide informed consent were inclusion criteria, while exclu-
sion criteria were chronic kidney or liver diseases, bleeding
disorders, severe diabetes mellitus, rheumatic diseases other
than osteoarthritis, neuromuscular disorders, malignancies
and systemic infections, chronic steroid use, major psycholog-
ical problems or history of alcohol or drug abuse, and evi-
dence of prior surgery in the involved hip.
Plasmid design and in vivo treatments
Plin2 knockdown was obtained through a RNA interference
(RNAi)-mediated strategy. Plin2 targeting (shPlin2) or
scrambled oligos were purchased from Life Technologies
and cloned into BLOCK-iT Pol II miR RNAi with EmGFP expres-
sion vector (Life Technologies). This technology allows to
follow transfected cells through the presence of GFP that is
transcribed in the same transcript of the pre-miRNA
targeting Plin2.
For Plin2 overexpression (overPlin2), Plin2 coding se-
quence was inserted into a modified pBI-CMV1 vector
(Clontech). pBI-CMV1 vector allows the cloning of two sepa-
rate coding sequences within the same vector. Summarizing,
one MCS 3XFlag-Plin2 was inserted, while GFP coding se-
quence was cloned in the other MCS. The expression of the
two proteins is driven by two different CMV minimal
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promoters guided by the same common enhancer, thus
allowing to directly identify Plin2 overexpressing fibres by
the detection of GFP expression. For controls experiments,
a pBI-CMV1 vector carrying only GFP sequences was used.
Knockdown or overexpression experiments were per-
formed by intramuscular injection of plasmids (shPlin2 or
overPlin2, respectively) in tibialis anterior (TA) muscle
followed by electroporation as described by Milan et al.14
In both shPlin2 and overPlin2 experiments, after electropora-
tion, muscles were collected 10 days after surgery.
In some experiments of Plin2 down-regulation, mice were
intraperitoneally injected with rapamycin (LC Laboratories)
2 mg/kg in 2% carboxymethylcellulose once a day for 7 days
starting from the third day of transfection, while in scramble
animals, only vehicle was administered.
In denervation experiments (Plin2 down-regulation or
Plin2 overexpression), immediately after transfection, the sci-
atic nerve was surgically cut in one side, allowing the counter-
part leg to be used as control. In this case, muscles were
removed after 7 days from surgery and snap frozen in liquid
nitrogen for subsequent analyses.
Histology
Snap frozen TA muscles were cut into 10 μm sections with a
Leica CM1950 cryostat. Sections were immediately moni-
tored with a fluorescence microscope Leica DM5000B
equipped with a Leica DFC300-FX digital CCD camera. Cryo-
sections of shPlin2 and overPlin2 TA, compared with their
controls, were stained for succinate dehydrogenase (SDH).
Cross-sectional area (CSA) of shPlin2 or overPlin2 fibres (six
mice per group) was measured and compared with an equal
number of control fibres, transfected with scramble or empty
vector. A minimum of 700 fibres for each muscle was
analysed. Fibre CSA was measured using IMAGEJ software.
All data are expressed as the mean ± SEM. Comparisons with
P < 0.05 were considered statistically significant.
Gene expression analyses
Total RNA from TA muscle of six mice per group (shPlin2,
overPlin2, and the respective controls) was extracted using
TRIzol reagent (Invitrogen). cDNA was synthesized using
iScript™ cDNA Synthesis Kit (Bio-Rad) according to the manu-
facturer’s instructions. Real-time RT–PCR was performed by
using iTaq™ Universal SYBR Green Supermix (Bio-Rad) and Ro-
tor gene Q 6000 system (QIAGEN GmbH, Germany). All data
were normalized to GAPDH expression. All oligonucleotide
pre-designed primers were from Bio-Rad. All information on
these primers are available at website www.bio-rad.com/
PrimePCR.
Protein extraction and western blot
Protein extracts were obtained starting from TA muscle of six
mice per group (shPlin2, overPlin2, and the respective con-
trols). A number of about 30 frozen slices (20 μm thick) were
collected from TA muscles and lysed as previously de-
scribed.14 The supernatant containing the total protein ex-
tract was quantified by BCA method (Thermo Fisher). Tissue
lysates were stored at 80°C until analysis. Twenty-five mi-
crograms of protein per well were loaded and separated in
12% SDS-polyacrilamide gel and transferred to a nitrocellu-
lose membrane, as already described.6 After blocking in 5%
non-fat dry milk/0.01% Tween 20-TBS, membranes were in-
cubated overnight with primary antibodies, as follows:
1:1000 rabbit polyclonal anti-Plin2 antibody (Lifespan Biosci-
ences); 1:1000 rabbit polyclonal anti-Plin5 (Lifespan Biosci-
ences); 1:1000 rabbit polyclonal anti-Plin3 (Lifespan
Biosciences); 1:500 rabbit monoclonal total GSK3β and P-
GSK3β(ser9) (Cell Signaling); 1:500 rabbit monoclonal 7F5
anti-p53 (Cell Signaling); and 1:1000 rabbit monoclonal total
S6 and P-S6(ser235/236) (Cell Signaling). Housekeeping
1:2000 goat anti-βActin (C-11) (Santa Cruz Biotechnology)
was used as loading control. The secondary anti-rabbit horse-
radish peroxidase-conjugated antibody (Bio-Rad) and bovine
anti-goat IgG-HRP antibody (Santa Cruz Biotechnology) were
used, followed by ECL detection (Santa Cruz Biotechnology).
Densitometry analysis of bands was performed using ImageJ
software.
Lipid analyses
Total lipids were extracted from TA muscle of six mice per
group (shPlin2, overPlin2, and the respective controls) follow-
ing the procedure described by Rodriguez-Estrada et al.,15
with some modification, necessary to adapt the method to
small quantity of the sample. Muscle sample (~60 mg) was
suspended in 6 mL of chloroform/methanol (2:1) solution
and homogenized for 2 min by ULTRATURRAX homogenizer
(IKA®-Werke GmbH & Co. KG, Staufen, Germany). Subse-
quently, samples were incubated at 50°C for 3 h and then
filtrated to remove the solid phase. After the addition of
3 mL of K2CO3 1 M aqueous solution, samples were incubated
at 4°C for 3 h. Apolar phase (lower phase) was transferred in
a fresh tube and rotary dried. Finally, lipid fraction was resus-
pended with 1 mL of hexane and stored at 20°C until the
analysis.
Lipid fractions [triacylglycerols (TAG), diacylglycerols
(DAG), and phospholipids (PL)] were separated by thin layer
chromatography as described as follow: total lipids
(resuspended with 0.3 mL) were spotted onto the 10 × 20
TLC silica gel 60 F254 plate (Merck KGaA, Darmstadt,
Germany). The TLC chamber was saturated beforehand with
hexane/diethylether (70:30) mix solution, and the elution
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was performed using the same mix. Then, the plate was dried
and the spot under UV light after spraying with 20,70-
dichlorofluorescein in ethanol. The isolated fractions were
identified on thin layer plates by comparing their Rf values
with that of known lipid standards. Spots corresponding to
PL, TAG, and DAG were scraped and recovered in separated
fresh vials. PL fraction was eluted by TLC to separate the sin-
gle PL component: phosphatidylcholine (PC) and phosphati-
dylethanolamine (PE). Elution mix was constituted by
chloroform/methanol/acetic acid/water (54:40:4:2). Spots of
the single PL were scraped and recovered in fresh vials.
Fatty acids (FAs) compositions of the single fraction were ob-
tained by gas chromatography (GC) analysis. Before GC analysis,
FAs were methylated by an acid-catalysed transmethylation
procedure, as follows: all single fractions were resuspended in
a tube with 2 mL of 10% acetyl chloride methanolic solution
and incubated at 50°C overnight. Subsequently, 2 mL of 6%
aqueous potassium carbonate solution were added to neutral-
ize pH, andmethylated FAs were extracted with 5 mL of hexane
and transferred in a fresh tube. The extraction step with hexane
was repeated twice. Samples were dried under nitrogen flow
and, then, resuspended with 0.3 mL of hexane. Samples were
collected in a vial for GC analysis.
The FA composition was determined by GC2010 Shimadzu
gas chromatograph (Shimadzu, Columbia, MD, USA)
equipped with a flame-ionization detector and a high polar
fused-silica capillary column (Chrompack CP-Sil88 Varian,
152 Middelburg, the Netherlands; 100 m, 0.25 mm i.d.; film
thickness 0.20 μm). Hydrogen was used as the carrier gas at
a flow of 1 mL/min. Split/splitless injector was used with a
split ratio of 1:40. Two microlitres of the sample were
injected under the following GC conditions: oven tempera-
ture started at 40°C and was held at that level for 1 min; then,
it was increased to 163°C at a rate of 2°C/min and held at that
level for 10 min, before being, once again, increased to 180°C
at 1.5°C/min and held for 7 min, and, finally, to 187°C at a
rate of 2°C/min; at last the temperature was increased to
220°C with a rate of 3°C/min and held for 25 min. Injector
temperature was set at 270°C, and detector temperature
was set at 300°C. Individual FA methyl esters were identified
by comparison with a standard mixture of 52 Component
FAME Mix (Nu-Chek Prep Inc., Elysian, MN, USA).
Nonadecanoic acid methyl ester was added as internal stan-
dard. The identification of isomers of 18:1 was based on com-
mercial standard mixtures (Supelco, Bellefonte PA, USA) and
published isomeric profiles.16 Total fat and FA content of sin-
gle fraction was expressed as g/100 g of muscle, while FA
profile was reported as g/100 g of total FA fraction.
Ceramides analyses
Ceramides were analysed in TA muscle of six mice per group
(shPlin2 and scramble), following the method described by
Groener et al.,17 with some modification. Briefly, an aliquot
of total lipids (~30 mg) was deacylated using 0.5 mL of
0.1 M NaOH in methanol at room temperature for 1 h. After
hydrolysis, 50 μL of the deacylated lipid were transferred in a
fresh vials and derivatized with the addition of 25 μL OPA re-
agent (Sigma-Aldrich, St. Louis, MO, USA) [5 mg OPA, 0.1 mL
ethanol, 5 L 2-mercaptoethanol, and 10 mL 3% (wt/vol) boric
acid adjusted to pH 9.0] for 30 min at room temperature.
OPA-derivatized lysoglycosphingolipids were separated by
use of a Prostar HPLC system (Varian) consisting of a Fluores-
cence Detector Spectra SYSTEM FL3000 (Thermo Finnigan,
Waltham, USA) with a C18 reverse phase column (ChromSep
HPLC Columns SS 250 mm × 4.6 mm including Holder with
ChromSep guard column Omnispher 5 C18). The mobile
phase was methanol/water 88:12 (vol/vol). The OPA-
derivatized lysoglycosphingolipids were quantified with a
fluorescence detector at lambda(ex) 340 nm and lambda(em)
435 nm. Peak identification was based on comparison of
the retention times with those of authentic calibrators of
the lysocompounds (NHexadecanoyl-D-erythro-sphingosine,
Matreya LLC, USA). Peak integration was performed with
Varian software. All samples were run in duplicate, and two
reference samples were included in every run.
Statistical analyses
All statistical tests used are reported in each figure legend.
Generally, data were analysed by two-tailed Student’s t-test.
For all graphics, data are represented as mean ± SEM.
Results
Plin2 knockdown promotes myofiber hypertrophy
Since Plin2 expression is increased in sarcopenic muscles and
during denervation,8 we investigated the role of Plin2 in mus-
cle mass by loss of function approach. Different oligos were
tested to selectively down-regulate Plin2 expression. The dif-
ferent shRNAs were cloned into bicistronic vectors that allow
the simultaneous production of the oligos and a GFP protein.
Therefore, by monitoring the GFP positive fibres, we can deter-
mine the efficiency of transfection and quantify myofiber area.
Our data showed that we efficiently reduced Plin2 tran-
script in vivo when compared with muscles that were
transfected with scramble oligos (Figure 1A and 1B). Impor-
tantly, the down-regulation of Plin2 is specific; indeed, the ex-
pression of Plin3 and Plin5, other two perilipins highly
expressed in skeletal muscles, was unaffected (Figure S1).
Then, we transfected shRNAs into adult myofibers for 10 days
and monitored the effect on muscle mass by quantifying the
CSA of the transfected fibres. Surprisingly, we found that inhi-
bition of Plin2 resulted in 30% increase of fibre size when
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compared with fibres that were transfected with scramble
oligos (Figure 1C, left columns). The same results are
represented as μm2 in Figure S2A (left columns). Interest-
ingly, fibre type was not affected by Plin2 down-regulation.
In fact, SDH staining showed no changes in distribution of
small β-oxidative mitochondria-rich vs. large glycolytic
mitochondria-poor fibres (Figure S3A), despite the high
transfection efficiency (Figure S3B).
Such a dramatic hypertrophy resembles the growth re-
ported when IGF1–AKT–mTOR pathway is acutely activated
in adult muscles.18 Therefore, to address whether this path-
way is affected by Plin2 down-regulation, we treated
transfected mice with rapamycin to block mTORC1-
dependent protein synthesis. Evaluation of phospho-S6 con-
firmed the efficient inhibition of the pathway after rapamycin
treatment (Figure S4A). Importantly, mTORC1 inhibition did
not reduce the hypertrophic effect of Plin2 down-regulation
(Figure 1C, right columns). The same results are represented
as μm2 in Figure S2A (right columns). Therefore, in a short
time frame (10 days), Plin2 down-regulation is sufficient to
promote muscle growth independently of mTORC1.
Plin2 down-regulation counteracts myofiber
atrophy after denervation
Because of the important hypertrophic effect after Plin2
down-regulation, we asked whether Plin2 down-regulation
was able to counteract denervation-induced myofiber atro-
phy. For this purpose, we down-regulated Plin2 expression
in denervated muscles. After 7 days from surgery (transfec-
tion and denervation), we collected muscles and measured fi-
bre size. Remarkably, Plin2 knockdown protected denervated
myofibers from muscle atrophy when shPlin2 fibres were
compared with not-transfected ones (Figure 1D). The same
results are represented as μm2 in Figure S2B. The experimen-
tal design of Plin2 down-regulation and denervation-
mediated atrophy is represented in Figure S4B.
Figure 1 Plin2 down-regulation in adult tibialis anterior (TA) muscle fibres. (A and B) RNAi-mediated knockdown of Plin2 revealed by real-time RT–PCR
(*P < 0.001) (A) and immunoblotting (B). (C and D) Cross-sectional area (CSA) of TA muscles upon knockdown of Plin2 expression. (C) CSA of adult TA
muscle fibres transfected with either shPlin2 or scramble. Left columns: *P = 0.001; right columns: the same, plus treatment with rapamycin: *P = 0.02.
(D) CSA of adult TA muscle fibres transfected with shPlin2 or scramble and undergone denervation performed at the same time of transfection. Left
columns: CSA of TA muscle fibres transfected with scramble; control vs. denervated, *P = 0.001. Right columns: CSA of TA muscle fibres transfected
with shPlin2; NO-shPlin2 indicates fibres that remained untransfected; GFP-shPlin2 indicates fibres transfected with the shPlin2;
*
P < 0.001. In all
cases, transfected fibres from six mice for each group were identified by GFP fluorescence, and a minimum of 700 fibres for each muscles were mea-
sured. Data are shown as mean ± SEM. P values refer to two-tailed Student’s t-test.
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Plin2 overexpression does not affect muscle CSA
We next asked whether Plin2 overexpression elicits the
opposite effect of Plin2 down-regulation. We therefore
transfected for 10 days adult TA muscles with an expres-
sion vector containing two different promoters to simulta-
neously encode Plin2 and a fluorescent tracker.
Quantitative RT–PCR and western blot analyses confirmed
Plin2 overexpression (Figure 2A and 2B) in adult TA. To
deeply investigate Plin2 overexpression phenotype, we
analysed and measured the area of transfected myofibers
identified through GFP fluorescence. Interestingly, in an
acute time window (10 days), the overexpression of Plin2
did not alter myofiber CSA when compared with controls
(Figure 2C). Consistently, in denervated muscles, the over-
expression of Plin2 did not further worsen muscle loss
(Figure 2D). The same results are represented as μm2 in
Figure S2C and S2D.
Plin2 modulation affects lipid content and
composition of TA muscle
It is known that muscle mass is modulated by lipids such as
ceramides, DAG, and specific phospholipid species. To get in-
sights into the mechanisms that promote muscle growth, we
quantified lipid composition in Plin2 knocked-down or over-
expressing muscles (Table 1). Plin2 down-regulation caused
a dramatic decrease of total TAG when compared with
scramble, while DAG remained unchanged. On the contrary,
overexpression of Plin2 caused an increase of TAG and a de-
crease of DAG content as compared with control.
The TAG composition was also analysed. FA profile was
modified by Plin2 down-regulation resulting in a decrease
of palmitoleic acid (C16:1c9) and oleic acid (C18:1c9) and in
an increase of the palmitic acid (C16:0) and stearic acid
(C18:0) as compared with controls (Table 2). These FAs are
products (C16:1c9 and C18:1c9) and substrates (C16:0 and
Figure 2 Plin2 overexpression in adult tibialis anterior (TA) muscle fibres. (A and B) Plin2 overexpression revealed by real-time RT–PCR and immuno-
blotting. TA muscles were transfected with vectors expressing Plin2 gene. (C) Cross-sectional area (CSA) of adult TA muscle fibres transfected with ei-
ther overPlin2 or control. (D) CSA of adult TA muscle fibres transfected with overPlin2 and undergone denervation at the same time of transfection. In
all cases, transfected fibres from six mice for each group were identified by GFP fluorescence, and a minimum of 700 fibres for each muscles were
measured. Data are shown as mean ± SEM.
*
P < 0.001, two-tailed Student’s t-test.
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C18:0) of Stearoyl-CoA Desaturase (SCD1), which inserts a cis-
double bond in Δ-9 position. It is therefore reasonable to ex-
pect that that Plin2 modulation in some way modify the activ-
ity of this enzyme. A useful parameter to estimate SCD1
activity is the desaturation index (DI).19 The analysis of
C16:1/C16:0 and C18:1/C18:0 DI showed that these ratios
were significantly lower in shPlin2 muscle compared with
controls (Figure 3A). At the same time, shPlin2 muscle
showed a significantly lower percentage of linoleic
(C18:2n6, 53%) and α-linolenic acid (C18:3n3, 47%). The
reduction of these FAs was accompanied by a concomitant
increase of some very-long-chain FA (VLCFA), in particular
C20:3n6, C20:4n6, C20:5n3, and C22:5n3. The first two VLFAs
are derived from the elongation of linoleic acid while the lat-
ter two from α-linolenic acid.
The overexpression of Plin2 also modified the FA profile (Ta-
ble 2). Stearic and palmitic acid was significantly reduced by
Plin2 overexpression because of SCD1 activity. In fact, the
higher C16:1/C16:0 and C18:1/C18:0 DI supports the idea that
SCD1 likely is activated when Plin2 is overexpressed (Figure
Table 1 Effect of Plin2 modulation on lipid fractions content in tibialis anterior muscle (g/100 g of muscle)
Plin2 down-regulation experiment Plin2 overexpression experiment
Scramble shPLIN2 SEM P-value Control overPLIN2 SEM P-value
Triacylglycerols 1.08 0.63 0.16 0.04 0.76 1.68 0.14 0.04
Diacylglycerols 0.39 0.44 0.14 0.46 0.49 0.05 0.02 <0.01
Phosphatidylethanolamine 0.13 1.08 0.21 <0.01 0.06 0.02 0.00 <0.01
Phosphatidylcholine 0.63 0.11 0.23 0.16 0.90 0.02 0.00 <0.01
SEM, standard error of the mean.
Table 2 Effect of Plin2 modulation on triacylglycerol FA profile in tibialis anterior muscle (g/100 g of total triacylglycerol fatty acids)
Plin2 down-regulation experiment Plin2 overexpression experiment
Scramble shPLIN2 SEM P-value Control overPLIN2 SEM P-value
C10:0 0.27 0.90 0.09 <0.01 0.44 0.37 0.11 0.40
C12:0 0.72 3.46 1.33 0.19 3.34 1.03 0.27 0.25
C14:0 2.88 5.59 0.53 0.01 3.82 4.52 0.26 0.08
C14:1t9 0.28 0.61 0.05 <0.01 0.24 0.20 0.12 0.62
C15:0anteiso 0.15 0.40 0.08 0.07 0.13 0.33 0.01 0.01
C15:0 0.64 1.11 0.14 0.05 0.68 0.70 0.05 0.12
C16:0 25.45 31.96 0.81 <0.01 30.63 29.35 0.17 0.05
C16:1c7 0.96 1.36 0.32 0.41 0.53 1.07 0.01 0.02
C16:1c9 8.22 4.34 0.41 <0.01 2.89 5.15 0.04 0.02
C17:0anteiso 0.12 0.23 0.02 <0.01 0.58 0.40 0.06 0.11
C17:0 1.46 1.90 0.26 0.28 1.69 1.19 0.28 0.49
C18:0 5.58 13.47 1.15 <0.01 14.53 10.03 0.19 0.10
C18:1t6–8 0.18 0.16 0.08 0.83 0.38 0.37 0.05 0.01
C18:1t9 0.32 0.41 0.16 0.70 0.20 0.19 0.04 0.03
C18:1t10 0.26 0.28 0.06 0.82 0.20 0.17 0.05 0.26
C18:1t11 0.14 0.49 0.19 0.24 0.46 0.41 0.21 0.51
C18:1t12 0.27 0.77 0.32 0.32 0.36 0.46 0.11 0.15
C18:1c9 25.50 16.21 1.46 <0.01 30.32 36.52 0.70 0.02
C18:1c11 2.12 1.16 0.12 <0.01 1.22 1.64 0.04 0.04
C18:2n6 19.80 9.25 1.24 <0.01 2.48 2.88 0.12 0.03
C20:0 0.04 0.21 0.06 0.05 0.38 0.23 0.03 0.01
C18:3n6 0.18 0.39 0.06 0.05 0.10 0.07 0.02 0.36
C18:3n3 1.17 0.62 0.05 <0.01 0.40 0.53 0.01 0.03
C20:3n6 0.43 1.59 0.18 <0.01 0.21 0.27 0.11 0.41
C20:4n6 0.18 0.96 0.26 0.05 2.07 1.14 0.04 0.03
C20:5n3 0.13 0.25 0.07 0.04 0.19 0.19 0.05 0.21
C24:0 0.87 0.47 0.13 0.05 0.40 0.46 0.22 0.45
C22:5n3 0.25 0.47 0.08 0.02 1.04 0.90 0.08 0.15
SFA 38.45 60.12 3.10 <0.01 56.63 48.18 0.83 0.08
PUFA 24.49 14.74 1.45 <0.01 6.49 5.57 0.18 0.11
MUFA 38.24 25.77 2.01 <0.01 36.78 46.16 0.91 0.02
MCFA 41.15 51.85 1.79 <0.01 44.97 44.28 1.04 0.07
LCFA 55.51 43.19 1.83 <0.01 50.64 52.85 1.35 0.02
VLCFA 4.51 5.57 0.56 0.22 4.30 2.78 0.28 0.41
LCFA, long-chain fatty acid (17 < C < 20); MCFA, medium-chain fatty acid (10 < C < 18); MUFA, monounsaturated fatty acid; PUFA, poly-
unsaturated fatty acid; SEM, standard error of the mean; SFA, saturated fatty acid; VLCFA, very-long-chain fatty acid (C < 19).
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3B). Moreover, Plin2 overexpression triggered high levels of
linoleic (+16%) and α-linolenic acid (+32%) and lower levels of
VLCFA as a possible consequence of a reduced elongase activity.
Finally, we quantified phosphatidylcholine (PC) and
phosphatidylethanolamine (PE), the two most abundant
phospholipid species in mammalian cell membranes. We
found a significant decrease of PC upon overexpression of
Plin2, while Plin2 down-regulation did not trigger significant
changes. Conversely, PE was highly increased after Plin2
down-regulation and decreased when Plin2 was
overexpressed (Table 1).
Plin2 modulation also affected FA profile of PE fraction
(Table 3). PE is constituted principally by C16:0, C18:0, and
C20:4n6. Plin2 overexpression caused a significant modifica-
tion of PE acidic profile, while no effect was observed after
Plin2 down-regulation. Particularly, in overPlin2 TA, we
observed a higher content of C16:0 and C18:0 and a dramatic
reduction of C20:4n6.
Since PC:PE ratio can influence energy metabolism20 and
plays a role in skeletal muscle contractile function,21 we de-
termined the PC:PE ratio in shPlin2 and overPlin2. A signifi-
cant decrease in PC:PE ratio was observed in shPlin2
muscles compared with controls, but not in overPlin2 mus-
cles (Figure 4), suggesting that Plin2 could affect muscle mass
through a modulation of the PC:PE ratio.
Modulation of Plin2 expression affects lipogenesis
The above reported results suggest that modulation of Plin2
expression impacts on intramuscular lipid content and com-
position. In order to get insights on such effect, we
Figure 3 Stearoyl-CoA desaturase 1 (SCD1) saturation indexes in tibialis anterior muscle after Plin2 modulation. Desaturation indexes of C16:1/C16:0
(*P = 0.002) and C18:1/C18:0 (*P = 0.003) in Plin2 down-regulated muscle (shPlin2) vs. scramble. Desaturation indexes of C16:1/C16:0 (*P < 0.001) and
C18:1/C18:0 (*P = 0.001) in Plin2 overexpressed muscle (overPlin2) vs. control (B, n = 4). Data refer to six samples for each group. Data are shown as
mean ± SEM. P values refer to two-tailed Student’s t-test.
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investigated the expression of genes involved in lipid metab-
olism: DAG acyltransferase 2 (DGAT2) that catalyses the con-
version of DAG into TAG; stearoyl CoA desaturase 1 (SCD1);
sterol regulatory element-binding protein 1 (SREBP1), a key
transcription factor regulating the expression of genes re-
quired for the de novo lipogenesis; and adipose triglyceride
lipase (ATGL) that is involved in lipolysis of TAG into DAG.
We performed quantitative RT–PCR comparing shPlin2 and
overPlin2 muscles with their respective controls and found
that DGAT2 significantly decreased when Plin2 was
knocked-down and increased after Plin2 overexpression
(Figure 5A and 5B). The expression of SCD1 and SREBP1 de-
creased upon Plin2 down-regulation and did not change upon
Plin2 overexpression (Figure 5C–5F). Furthermore, the ex-
pression of ATGL was not altered by either Plin2 down-
regulation or Plin2 overexpression (Figure 5G–5H). Alto-
gether, these results suggest that Plin2 controls lipid
content by regulating master genes of lipogenesis.
Plin2 down-regulation affects ceramide content
Recent data indicate that oleic acid, the major product of
SCD1, plays an important role in the regulation of the intra-
cellular ceramide synthesis. Since Plin2 down-regulation al-
ters SCD1 expression and the levels of oleic acid, we
Table 3 Effect of Plin2 modulation on phosphatidylethanolamine FA profile in tibialis anteriormuscle (g/100 g of total phosphatidylethanolamine fatty
acids)
Plin2 down-regulation experiment Plin2 overexpression experiment
Scramble shPLIN2 SEM P-value Control overPLIN2 SEM P-value
C14:0 7.42 10.93 2.13 0.29 5.77 7.68 0.47 0.10
C15:0 1.98 1.54 0.60 0.26 1.35 1.09 0.03 0.02
C16:0 32.76 24.04 7.11 0.31 23.00 44.07 0.74 0.00
C16:1c7 0.01 0.77 0.14 0.01 0.00 1.08 0.68 0.38
C16:1c9 0.02 0.38 0.15 0.15 0.00 0.40 0.05 0.02
C17:0anteiso 0.02 0.38 0.09 0.03 0.00 1.03 0.04 0.00
C17:0 2.83 0.73 0.49 0.02 5.42 2.53 0.47 0.05
C18:0 23.96 25.66 4.60 0.80 23.47 27.07 0.05 <0.01
C18:1c9 6.82 9.55 3.53 0.04 6.63 6.59 0.20 0.92
C18:2n6 0.69 0.65 0.23 0.91 1.80 0.76 0.06 0.01
C20:3n6 0.39 1.47 0.46 0.90 0.51 1.36 0.70 0.48
C20:4n6 19.85 20.82 1.39 0.34 29.10 6.33 0.57 0.01
C22:5n3 3.24 3.07 1.38 0.93 2.95 0.00 0.11 <0.01
SFA 68.98 63.28 3.26 0.28 59.02 83.47 1.01 <0.01
PUFA 24.17 26.02 1.85 0.32 34.36 8.45 1.48 0.01
MUFA 6.85 10.70 3.62 0.05 6.63 8.08 0.55 0.21
MCFA 45.05 58.76 4.96 0.31 35.54 57.88 2.04 0.02
LCFA 31.47 35.87 6.20 0.58 31.90 34.42 1.35 0.03
VLCFA 23.48 5.37 1.84 <0.01 32.56 7.69 0.68 <0.01
LCFA, long-chain fatty acid (17 < C < 20); MCFA, medium-chain fatty acid (10 < C < 18); MUFA, monounsaturated fatty acid; PUFA,
polyunsaturated fatty acid; SEM, standard error of the mean; SFA, saturated fatty acid; VLCFA, very-long-chain fatty acid (C < 19).
Figure 4 Phosphatidylcholine (PC) and phosphatidylethanolamine (PE) ratio in tibialis anterior muscle after Plin2 modulation. Left columns: shPlin2
muscles compared with scramble (n = 6 mice per group), *P = 0.001. Right columns: overPlin2 muscles compared with controls (n = 6 per group). Data
are shown as mean ± SEM. P values refer to two-tailed Student’s t-test.
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checked ceramides content in shPlin2. The total content of
ceramide was reduced by 80% in shPlin2 TA muscles as com-
pared with controls (Figure 6A). Moreover, since ceramides
are precursors of sphingolipids, including sphingomyelin,
sphingosine, and glucosylceramide, we checked the content
of these lipids and found that they were significantly
decreased upon Plin2 down-regulation (Figure 6B–6D).
Moreover, previous studies demonstrated that ceramides
indirectly activate GSK3β by promoting its dephosphorylation
at ser922 and increase p53 protein.23,24 Consistently, we
Figure 5 Relative expression of relevant genes involved in lipid metabolism in tibialis muscle after Plin2 modulation. (A, C, E, and G) Plin2 down-reg-
ulation. (B, D, F, and H) Plin2 overexpression. (A and B) DAG acyltransferase 2 (DGAT2). (C and D) Stearoyl CoA desaturase 1 (SCD1). (E and F) Sterol
regulatory element-binding protein 1 (SREBP1). (G and H) Adipose triglyceride lipase (ATGL). Results were normalized to GAPDH RNA expression. Data
refer to six samples for each group. Data are shown as mean ± SEM.
*
P < 0.02, two-tailed Student’s t-test.
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observed an increase of the phosphorylated form of
GSK3β and a reduction of p53 expression in shPlin2
muscle (Figure 6E and 6F). As a whole, shPlin2 muscle
displays a dramatic decrease of ceramide content that could
be at least in part responsible for CSA increase via inhibition
of GSK3β.
Plin2 level increases with ageing in human muscles
and affects lipid composition
Our recent data indicate that Plin2 expression increases with
ageing in human skeletal muscle.7,8 To check whether the
results obtained in our animal model have a counterpart in
humans, we analysed lipid composition in VL muscle biopsies
of young (<40 years) and old (>70 years) patients undergo-
ing hip surgery. Consistent with the above results, muscle
samples from old patients (which display higher levels of
Plin2, Figure 7A) showed a significant increase of TAG and
DAG when compared with young (Figure 7B). We also mea-
sured desaturation index (C16:1/C16:0 and C18:1/C18:0 DI)
and phospholipid composition in these samples. In agree-
ment with animal data, the C16:1/C16:0 and C18:1/C18:0 DI
were higher in old subjects compared with young
(Figure 7C). PE levels were similar between young and old,
while PC levels were significantly lower in old compared with
young (Figure 7D). However, the PC:PE ratio remained
unchanged in the two different age groups (Figure 7E).
Figure 6 Ceramide content and protein expression of GSK3β and p53 in tibialis anterior (TA) muscles after Plin2 modulation. (A–D) Total ceramide (A),
sphingomyelin (B), sphingosine (C), and glucosylceramide (D) contents in shPlin2 muscles compared with scramble. (E) Representative immunoblots of
protein extracts from scramble and shPlin2 muscle for the indicated antibodies. (F) Relative expression levels of Plin2, ratio between phosphorylated
and total GSK3β, and p53 proteins in scramble and shPlin2 TA muscles. Data are normalized to actin expression and refer to six samples for each group.
Data are shown as mean ± SEM. *P < 0.001, two-tailed Student’s t-test.
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FA composition of TAG in human samples is summarized in
Table 4. Young and old subjects showed a different composi-
tion of FA profile. In particular, the muscles of old subjects are
characterized by lower SFA and higher MUFA. These data are
very similar to those obtained in mice suggesting a possible
conserved function of Plin2 in lipids regulation.
Discussion
It is well established that alterations of lipid metabolism in
non-adipose tissue lead to an excess of lipid metabolites
(including ceramides) that trigger lipotoxicity, cellular
dysfunction, and metabolic disorders. Recent findings indi-
cate that high levels of Plins are associated with deregulation
of intracellular lipid deposition causing disease onset. In
particular, high levels of Plin2 have been found in patients
affected by liver steatosis, atherosclerosis, obesity, cardiovas-
cular diseases, type 2 diabetes, and muscle weakness.6
Consistently, Plin2 down-regulation ameliorates the above
described diseases in mice.6 In previous studies, we reported
that Plin2 is differently expressed in young and old subjects,
being particularly elevated in muscles of inactive old people.7
In these subjects, we observed that Plin2 accumulation is as-
sociated with lower muscle mass and strength and paralleled
by increased expression of p53 and atrophy-related genes
such as Atrogin-1 and MuRF-1.7,8 In a recent study, obese
Figure 7 Plin2 expression and lipid content and composition in vastus lateralismuscle of young and old patients. (A) Relative expression level of Plin2,
*P = 0.001. (B) Total triglycerides (TAG) and diacylglycerols (DAG), *P = 0.04 and *P = 0.002, respectively. (C) Desaturation indexes of C16:1/C16:0 and
C18:1/C18:0, *P = 0.02 and *P = 0.03, respectively. (D) Phosphatidylcholine (PC), *P = 0.04, and phosphatidylethanolamine (PE) content. (E) PC/PE ratio.
Data refer to 10 samples for young group and 9 samples for old group. Data are shown as mean ± SEM. P values refer to two-tailed Student’s t-test.
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type 2 diabetes STD fatty rats were reported to have high
content of Plin2 and lower CSA in type IIb muscle fibres.25
However, the role of Plin2 in skeletal muscle homeostasis is
still not completely understood. In the present study, we took
advantage of in vivo genetic manipulations to dissect the
function of Plin2 in adult muscles. Acute Plin2 down-
regulation was sufficient to increase the CSA of TA, while its
overexpression did not change muscle mass. This shPlin2-
mediated hypertrophy appears largely mTORC1 independent,
suggesting that Plin2 may modulate muscle growth in an un-
usual way.
The role of Plin2 in determining lipid droplet fate is well
known, being the central core protein regulating intracellular
lipid accumulation and metabolism. Moreover, changes of
Plin2 greatly affect lipid composition in several tissues includ-
ing skeletal muscle.26,27 Accumulation of intramuscular lipids
plays a pathogenic role in insulin resistance and type 2 diabe-
tes.28 Finally, several recent studies highlighted the involve-
ment of fatty acids and their metabolites, such as DAG and
ceramides, in blocking muscle growth and altering myofiber
metabolism.13,29,30 For this reason, we investigated how the
modulation of Plin2 expression could affect the lipid metabo-
lites in adult skeletal muscle and whether this can account for
the observed effect on myofiber size. Our gain and loss of
function experiments confirmed that Plin2 control lipid
composition and expression of genes related to lipid biosyn-
thesis. In agreement with previous studies,26,27 we found that
SREBP1 and DGAT2 are greatly modulated by Plin2. SREBP1 is
the master regulator of genes involved in de novo lipogene-
sis,31 while DGAT2 is the enzyme of the last step in the path-
way of TAG synthesis.32–34 Different studies showed that
these two genes are involved in lipid accumulation and in
the control of muscle mass. DGAT2 overexpression increases
TAG, ceramide, and DAG content in muscle and liver,31,35
while SREBP1 promotes skeletal muscle atrophy of both dif-
ferentiated myotubes in vitro and tibialis muscle in vivo.36,37
Contrary to our expectations based on previous data,8 the
overexpression of Plin2 in our mouse model did not yield any
variation of CSA, although lipid profile resulted affected. In
the present experimental setting, DGAT2, SCD1, and SREBP1
expression decreases upon Plin2 down-regulation, while
DGAT2 but neither SREBP1 nor SCD1 expression increases
upon Plin2 overexpression. It is thus likely that the observed
shPlin2-mediated muscular hypertrophy relies on the down-
regulation of SCD1 and SREBP1 but not DGAT2. It is possible
that this lack of effect of Plin2 overexpression on myofiber
size is due to the short time course (mice sacrificed after
10 days from transfection). Further studies are needed to
clarify this point.
Besides lipid content, the regulation of Plin2 expression
also affects the FA profile, especially of TAG fraction. We ob-
served a higher level of C18:0 and C16:0 and a decrease of
the relative MUFA (C18:1c9 and C16:1c9) when Plin2 was
down-regulated, while opposite results were obtained when
Plin2 was overexpressed. It is unknown whether changes in
TAG FA composition affect muscle growth; nevertheless,
C18:0 and C16:0 represent the substrates of SCD1 enzyme,
while C18:1c9 and C16:1c9 are the products.38,39 Both SCD1
expression and DI, which represents a useful tool to estimate
SCD1 activity,40 are significantly affected by Plin2. High levels
of SCD1 has been reported in patients affected by obesity as
well as type 2 diabetes41 and has been suggested to impact
muscle structure and quality.13,42,43 Moreover, SCD1 activity
regulates ceramide synthesis, and in particular, SCD1 defi-
ciency reduces total ceramide content in skeletal muscle.44
Importantly, Plin2 down-regulation reduced ceramide con-
tent by decreasing SCD1 expression. The reduction of
ceramides releases the anabolic pathways from their inhibi-
tory action45 and therefore promotes protein synthesis and
muscle hypertrophy. Moreover, ceramides promote muscle
wasting through the activation of apoptotic pathways.13 In
particular, apoptosis can be activated via dephosphorylation
at serine 9 of GSK3β, which in turn interacts with p53 in re-
sponse to various cellular stresses.21,46–48 In agreement with
these findings, in shPlin2 muscle, we observed an increase
of phosphorylated, inactive GSK3β form and a decrease of
p53 level. p53 is known to play a role in muscle wasting, lead-
ing to skeletal muscle atrophy and muscle stem cell perturba-
tion.49,50 As our previous data suggested an involvement of
Table 4 Triacylglycerol content (g/100 g of muscle) and FA profile (g/
100 g of total triglyceride fatty acids) in vastus lateralis muscle biopsies
from subjects of different age
Young SEM Old SEM P-value
Total 1.12 0.81 3.32 0.78 <0.01
C10:0 4.03 0.87 1.06 0.82 0.02
C10:1c9 1.03 0.14 0.65 0.13 0.05
C12:0 1.77 0.25 1.00 0.23 0.04
C14:0 6.49 0.81 4.73 0.77 0.13
C14:1c9 1.42 0.21 1.25 0.20 0.56
C15:0 0.92 0.12 0.60 0.11 0.06
C16:0 32.13 2.62 28.97 2.48 0.39
C16:1c9 0.94 0.44 1.43 0.42 0.43
C17:0anteiso 2.38 1.92 7.21 1.83 0.09
C17:0 1.19 1.19 0.88 0.22 0.35
C18:0 13.98 1.15 9.08 1.09 0.01
C18:1c9 1.68 4.66 16.78 4.42 0.03
C18:1c11 1.23 0.42 1.54 0.40 0.59
C18:2c9c12 8.25 2.19 10.86 2.08 0.40
C20:0 1.31 0.26 0.66 0.25 0.05
C18:3c9c12c15 0.58 0.09 0.48 0.09 0.44
C20:3n3 0.44 0.09 0.22 0.08 0.05
C20:4n6 17.08 2.81 11.76 2.67 0.19
C22:5n3 3.16 0.81 0.85 0.77 0.04
SFA 64.20 3.27 54.18 3.11 0.04
MUFA 6.30 4.14 22.65 3.94 0.02
PUFA 29.51 0.15 24.17 2.44 0.15
MCFA 52.30 2.62 47.78 2.49 0.23
LCFA 25.72 3.62 38.74 3.50 0.02
VLCFA 21.99 3.51 13.49 3.01 0.05
LCFA, long-chain fatty acid (17 < C < 20); MCFA, medium-chain
fatty acid (10< C < 18); MUFA, monounsaturated fatty acid; PUFA,
polyunsaturated fatty acid; SEM, standard error of the mean; SFA,
saturated fatty acid; VLCFA, very-long-chain fatty acid (C < 19).
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muscle wasting,8 we investigated the expression of atrophy-
related genes Myostatin, Atrogin-1, and MUSA-1 in shPlin2
muscles, but no changes were detected (data not shown).
However, GSK3β is also a negative regulator of skeletal mus-
cle growth, as it inhibits protein synthesis.51,52 The inhibition
of GSK3β is in fact a potential strategy for the prevention or
treatment of muscle atrophy.51 In agreement with literature
data,53–55 the inhibition of GSK3β resulted independent from
the AKT–mTOR pathway, as the level of the phosphorylated
form of AKT (P-AKT-ser473) did not change in shPlin2 muscles
(data not shown). Another pathway should therefore exist
that can inhibit GSK3β.
Finally, also phospholipids may contribute to the muscle
phenotype because PE has been reported to affect skeletal
muscle growth20,21 and PC:PE ratio is inversely correlated to
insulin sensitivity.21,56,57 Recent studies in mice showed an
impaired calcium uptake and muscle weakness when PE is
reduced and consequently, the PC:PE ratio is increased.58,59
Interestingly, we found that Plin2 down-regulation, but not
Plin2 overexpression, decreased PC:PE ratio due to a strong
increase in PE. This phospholipid change may also contribute
to the growth-promoting action of Plin2 down-regulation.
Altogether, our data suggest that Plin2 is involved in the
regulation of intracellular content of lipid species, some of
which are involved in muscle mass regulation. However,
inhibition of the degradation pathways is not sufficient to
promote muscle growth. In fact, both muscle-specific
autophagy deficient mice and knockout for the ubiquitin
ligases such as Atrogin-1 or MuRF1 do not show muscle
hypertrophy.60,61 Muscle growth instead depends on the
increase of protein synthesis as shown by the inducible
muscle-specific AKT transgenic mice that displayed muscle
growth.61 Therefore, it is possible that Plin2 could be a still
unrecognized negative regulator of protein synthesis and
therefore of muscle growth, likely acting through its control
on intracellular lipid content and composition, in particular
on ceramides and PE. Further studies are needed to clarify
this aspect.
Human ageing is characterized by a progressive loss of
skeletal muscle mass and regenerative capacity.62,63 In previ-
ous studies, we demonstrated that VL muscle biopsies of el-
derly people contain higher Plin2 content when compared
with young patients.7,8 In addition, the level of Plin2 posi-
tively correlates with lower quadriceps strength and in-
creased expression of atrophy markers.7,8 For this reason,
we investigated whether the lipid profile found on muscle bi-
opsies from old subjects was at least in part similar to that
observed on mice muscles. Consistent with our mouse data
on overPlin2 muscles, old subjects displayed higher muscular
TAG and DAG levels as well as increased DI and lower levels
of PC with respect to young people. Moreover, the FA profile
of TAG also recapitulates the findings obtained in mice. In
fact, biopsies of old patients displayed a decrease of C18:0,
an increase of C18:1c9, and a decrease of C20:3n3 and
C22:5n3. Therefore, a certain degree of similarity exists be-
tween mouse and human muscle lipid profile, notwithstand-
ing the fact that the two muscles investigated (TA in mice
and VL in humans) have a different fibre type composition
and that the first experimental model (mouse) entailed an
acute stress phenomenon (transfection or denervation),
while the second (patients) reflected a chronic situation
(advanced age or prolonged inactivity). Further studies are
granted to clarify the relationship among Plin2 accumulation,
muscle mass modulation, and human ageing.
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Figure S1. Representative immunoblot showing the specific-
ity of Plin2 downregulation by in vivo RNAi technique in adult
Tibialis anterior (TA) muscle fibers. TA muscles were
transfected with vectors expressing two different short
harpin RNAs (shRNAs) specific for Plin2. The expression of
Plin3 and Plin5 (two Plins present in skeletal muscle fibers)
in the same samples resulted unchanged, confirming the
specificity of shRNA only for Plin2.
Figure S2. A-B: Cross Sectional Area (CSA) of TA muscles upon
knockdown of Plin2 expression. A: CSA of adult TA muscle fi-
bers transfected with either shPlin2 or scramble. Left col-
umns: *p = 0.001; right columns: the same, plus treatment
with rapamycin: *p = 0.02. B: CSA of adult TA muscle fibers
transfected with shPlin2 or scramble and undergone dener-
vation; muscles were collected after 7 days from transfection;
NO-shPlin2 indicates fibers that remained untransfected,
GFP-shPlin2 indicates fibers transfected with the shPlin2;
*p < 0.001. C-D: CSA of TA muscles upon overexpression of
Plin2 expression. C: CSA of adult TA muscle fibers transfected
with either overPlin2 or control. D: CSA of adult TA muscle fi-
bers transfected with overPlin2 and undergone denervation;
muscles were collected after 7 days from transfection. In all
cases, transfected fibers from 6 mice for each group were
identified by GFP fluorescence, and CSA was measured after
7 days from transfection. Data are expressed as mean ± SEM.
p values refer to two-tailed Student’s t test.
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Figure S3. A: Representative images of succinate dehydroge-
nase (SDH) from Tibials anterior (TA) transversal sections iso-
lated from scramble and shPlin2 mice analyzed by SDH
staining. B: Fluorescence microscope images (in 5x magnifica-
tion) of a whole TA section of mouse transfected with
shPlin2, and the SDH respectively staining.
Figure S4. A: Western blot analysis showing the reduction in
S6 phosphorylation, demonstrating the corrected
mTORC1 inhibition by rapamycin treatment; CMC:
carboxymethylcellulose. B: Schematic representation of Plin2
downregulation and denervation experiments performed in
the same mouse.
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